UCB, Q-State deal

UCB and Q-State partnered to discover and develop therapeutics against undisclosed genetic targets to treat epilepsy subtypes, including genetically defined childhood epilepsy. Q-State will apply its proprietary Optopatch platform to build disease models and characterize neuronal dysfunction using stem cell-derived neurons from epilepsy patients. The companies will collaborate to identify therapeutics from their combined small molecule libraries...